Search
Now showing items 21-30 of 88
The value of neuroendocrine markers in non-small cell lung cancer: a comparative immunohistopathologic study
(1994)
In order to estimate the value of immunohistochemical identification of neuroendocrine (NE) differentiation markers in non-small cell lung carcinomas (NSCLCs), we investigated the expression of five neuroendocrine and ...
Intensive chemotherapy with high-dose epirubicin every 2 weeks and prophylactic administration of filgrastim in advanced breast cancer
(1994)
50 women with advanced breast cancer were treated with an intensified regimen which consisted of high-dose epirubicin (110 mg/m2) every 2 weeks and filgrastim (5 μg/kg) subcutaneously for 13 days, starting 24 h after ...
Tropisetron in the prevention of acute nausea and vomiting in patients treated with high dose epirubicin
(1998)
Tropisetron is a novel selective antagonist of the type-3 serotonin (5- HT3) receptor, with proven efficacy in the control of emesis related to cancer treatment. Epirubicin in doses of >100 mg/m2 has a high emetogenic ...
Primary lymphoma of the pericardium: Report on a 'cured' case and review of the literature
(1994)
This report describes a 62-year-old man with a primary diffuse, immunohistochemically proven B-cell lymphoma of large noncleaved cell (centroblastic) type of the pericardium. The patient responded completely to systemic ...
Prognostic factors influencing complete response to treatment and survival of patients with nasopharyngeal cancer
(1998)
The identification of prognostic factors influencing local control and survival of patients with nasopharyngeal cancer (NPC) might help in pointing out those patients who would probably benefit from primary treatment. A ...
No response or survival improvement in small cell lung cancer after sequential chemotherapy with three non-cross resistant drug regimens - a pilot study
(1991)
In a pilot phase II study we have treated 25 patients with small cell lung cancer by utilizing 3 non-cross resistant drug regimens given in a sequential fashion in combination with radiotherapy to the primary tumor. VAC ...
Primary extranodal non Hodgkin's lymphoma of the head and neck in adults: A clinicopathological comparison between tonsillar and non tonsillar lymphomas
(1998)
Primary extranodal NHL of the head and neck (HN-NHL) accounts for 10-20% of all cases of NHL. Despite their frequency, the natural history and biological behaviour of these lymphomas is poorly understood. In this study we ...
Serum anion gap in multiple myeloma patients
(1992)
The aim of this study was, first, to reconfirm the low serum anion gap (SAG) in multiple myeloma patients and, second, to propose the possible pathophysiologic mechanisms involved. We studied 20 patients with IgG multiple ...
Paclitaxel by three-hour infusion and carboplatin in advanced carcinoma of nasopharynx and other sites of the head and neck: A phase II study conducted by the Hellenic Cooperative Oncology Group
(1997)
Background: Paclitaxel has been demonstrated to have significant activity in recurrent or metastatic head and neck cancer (HNC). In addition, the combination of paclitaxel and cisplatin is active in untreated patients with ...
Carboplatin alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: A hellenic co-operative oncology group study
(1996)
We compared, in a multicentric randomised prospective study, the efficacy and toxicity of carboplatin 400 mg/m2 as a single agent (CB) to a combination of carboplatin 300 mg/m2, epirubicin 50 mg/m2 and cyclophosphamide 500 ...